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Abstract
In the face of an almost unprecedented threat of a global pandemic of influenza it is imperative that stockpiling of appropriate drugs and
devices begin now. One vital device is an appropriate syringe for delivering vaccine. With the potential for millions to be infected and the
vaccine supply severely stretched it is imperative that the syringe used to vaccinate waste as little vaccine as possible and thus allow for a
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daximum number of persons to be vaccinated. Our study tested seven leading candidate vaccine syringes for dosing accuracy, dose-capacity
er vial, medication wastage and a battery of ergonomic features. One device, the Flu+TM syringe, proved superior to the others in all important
ategories, possibly due to its low dead-space volume and its dosing accuracy. The data suggest that switching to this device from any of
he others tested would provide between 2 and 19% additional vaccine doses per vial if the current 10-dose vials are used. Extrapolations
rom this data suggest that many thousands to millions of additional persons could be vaccinated in mass campaigns. Use of a syringe of this
ype, and the vaccine savings that would accrue, would likely be important in reducing morbidity and mortality in the event of a pandemic of
nfluenza.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
Hardly a day passes without a new alarm raised regarding
5N1 avian influenza. Its steady march westward from Asia,
ts striking case:mortality rate and the expectation that it will
oon ‘humanize’ (become easily transmissible from person to
erson) are causing tremors throughout the world [1]. At the
ack of everyone’s mind is the question, ‘could this become
nother 1918?’ The influenza pandemic of 1918 may well
ave been the worst catastrophe in human history. The most
ecent estimates, which now include deaths from India and
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China, are that as many as a 100 million people worldwide
lost their lives [2].
Unlike yearly epidemics, pandemic flu viruses have a
predilection for young, healthy persons, whom they attack
with astonishing virulence. It was not uncommon in 1918
for a young person to go to bed feeling fine, wake up achy
and feverish, be bedridden by noontime and be dead before
sundown [3].
Influenza experts have long predicted a 1918-like
influenza pandemic from southeastern Asia, the region
from which the SARS coronavirus emerged [4,5]. All three
influenza pandemics in the last century have come from this
region. The 1918 pandemic took 3 weeks to circle the globe
in an age without commercial air travel. A pandemic today
might take as little as 2 days [6–8]. A recurrence of 1918
would mean 100 million cases of flu in North America alone
and an equal number in Europe [4,7]. These would come in
two giant waves (if previous pandemics are a guide), the first
264-410X/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
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beginning in late fall and the second in spring. Upwards of
2 million deaths could result on each continent [9,10]. The
possible toll worldwide is almost unfathomable.
The health-care response during the first days into a pan-
demic would focus on vigorous, proactive public health mea-
sures such as isolation of those infected, closures of schools,
the obligatory wearing of masks, gloves and other protective
gear and frequent hand-washing [8,11–13]. Anti-influenza
drugs, which are currently in short supply, would play a
critical role, assuming resistance to them did not develop
quickly. The newer Neuraminidase Inhibitors, oseltamivir
and zanamivir, would be made available during the first wave
to key population groups in countries which have been wise
(and wealthy) enough to stockpile [14].
It is axiomatic that a vaccine will not be immediately
available, but will take several months to develop with cur-
rent technology [15,16]. Worldwide there are only a hand-
ful of manufacturers [17] who produce the vast majority of
influenza vaccines. It would require between 3 and 8 months
to produce and release a new influenza subtype vaccine,
meaning that no or limited doses of vaccine would be avail-
able in the first half year of the pandemic.
Pandemic preparedness involves stockpiling of the key
medical supplies known to be needed in the first months of
a pandemic (e.g. anti-virals) as well as those that are likely
to be in short supply when the vaccine is ready, most crit-
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The study compared the accuracy and reproducibility of
a 0.5 mL dose administered with each of seven device which
are being considered as stocking options in pandemic pre-
paredness (Table 1). We compared the total number of 0.5 mL
doses obtained from a 10-dose vial (5.0 mL) with the opti-
mal number of ‘expected draws’. From this we estimated the
number of persons who could be vaccinated with each device
per million vials purchased. Finally, we compared the ease
and speed of use of each device as determined by users.
2. Materials and methods
2.1. Number of syringes and users
Seventy study syringes per clinician were assessed by
five clinicians per site in nine European sites (3150 devices
in total). Forty-five clinicians (nurses and physicians) were
enrolled at three sites in Poland, three in Sweden and three in
the United Kingdom (England, Scotland, Wales) (Table 2).
Participating clinicians were required to have at least 6
months of injecting experience and to perform at least five
percutaneous injections (intramuscular, intradermal or sub-
cutaneous) per week. Sites varied from academic medical
centres to private clinics to regional medical centres and users
were felt to constitute a representative sample of injecting
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1 ttached
2 ttached
3 etached
4 etached
5 etached
6 etached
7 etachedcally syringes. The choice of syringe by stockpilers is not
erely of academic or financial interest; it will be a major
eterminant of life or death in a pandemic. Given the scale
f need for vaccine and the limited capacity of manufactur-
rs to supply it, shortages will be inevitable. Such will be the
utcry for vaccine that officials expect major social and polit-
cal upheavals [18]. It is therefore of paramount importance
o stock a syringe which will reduce vaccine wastage to a
inimum and thereby allow the greatest number of persons
o be vaccinated. In our experience, discussions on pandemic
reparedness often overlook the critical role of the ‘lowly’
yringe. We continue to do this at our own peril.
This article reports on a study which will inform officials
nd planners of the public health stakes in their choice of a
andemic syringe for vaccination. It is intended to help them
stimate the degree of vaccine wastage/savings they should
xpect with each potentially stockable device. We provide
nformation for estimating the additional number of individ-
als who might benefit from vaccination as a function of the
evice.
able 1
evices tested in current study
evice number Trade name/description Dose range (mL) N
Flu+ 0.25–1.0 A
SoloShot IX 0.5 (fixed) A
Plastipak Luer slip 0.0–1.0 D
Plastipak Luer slip 0.0–2.0 D
Injekt Luer slip 0.0–2.0 D
Monoject Luer slip 0.0–1.0 D
Terumo Luer slip 0.0–1.0 Dealth-care professionals.
.2. Products trialed
At enrollment, each clinician received seven 5 mL vials
f sterile saline (Abbott Laboratories, North Chicago, IL,
SA); 10 BD Flu+TM 0.25–1 mL variable dose syringes with
ttached 25 G 1 in. (25 mm) needles (BD, Franklin Lakes, NJ,
SA); 10 BD 0.5 mL SoloShotTM IX Auto-Disable Syringes
nd attached 25 G 1 in. needles; ten 1 mL BD PlastipakTM
uer slip syringes with detached 10 BD MicrolanceTM 25 G
in. needles; 10 BD 2 mL PlastipakTM Luer slip syringes
ith 10 BD MicrolanceTM 25 G 1 in. needles; ten 2 mL B
raun InjektTM Luer slip syringes with 10 detached B Braun
tericanTM 25 G 1 in. needles (B Braun, Melsungen, Ger-
any); ten 1 mL Tyco MonojectTM Luer slip syringes with 10
etached Tyco MonojectTM 25 G 1 in. needles (Tyco, Mans-
eld, MA, USA); ten 1 mL TerumoTM Luer slip syringes with
0 detached Terumo NeolusTM 25 G 1 in. needles (Terumo,
euven, Belgium). These devices were chosen based on con-
acts with pandemic preparedness planners in Europe who
xation Needle gauge (G) Needle length (in.) Manufacturer
25 1 BD
25 1 BD
25 1 BD
25 1 BD
25 1 B Braun
25 1 Tyco
25 1 Terumo
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Table 2
Participating centres
Poland Sweden UK
Szpital Bielanski, Warsaw University Hospital Malmo, Malmo East Oxford Health Center, Oxford, England
NZOXZ Sana S.C. Policlinic, Warsaw Helsingborg Hospital, Helsingborg Prince Charles Hospital, North Glamorgan NHS Trust, Merthyr Tidfil, Wales
Miedzyleski District Hospital, Warsaw University of Lund Hospital, Lund Fife NHS Primary Care Trust, Kirckaldy, Scotland
indicated that they were considering stocking these or simi-
lar syringes. Saline was chosen as a substitute for influenza
vaccine based on similarity of physical properties as well as
saline’s overall safety profile for participants.
2.3. Study process
The order of use of each syringe was randomized. Study
staff neither intentionally identified nor concealed the identity
of the device being used. All devices were CE-marked and
branded, thus it was impossible to blind users to the man-
ufacturer. Staff weighed a 5 mL vial containing saline in a
highly-sensitive electronic balance (Excellence SXTM Ana-
lytical Balance, Mettler-Toledo, OH, USA) and gave it to the
participant with instructions to draw up consecutive doses
of 0.5 mL and inject them into a plastic tub on the balance
using the drawing-up and injection techniques they custom-
arily used in practice; no training on technique was given
beyond a simple verbal explanation of the function of each
syringe. Opportunity was given to the users to practice with
the device beforehand, as desired.
The goal for the user was to draw up the maximum num-
ber of full doses from the vial. Each dose was weighted (Vx)
and a running sum of weights was kept (sum Vx). When
the sum Vx approached the expected maximum the vial con-
tained, the vial was again weighed. If there was adequate
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2.5. Reproducibility
Standard deviations (S.D.) were used to assess the repro-
ducibility of results for the different variables (within device,
within vial, within person, within centre, within country).
2.6. Accuracy
The target value for each injection was 0.500 g. Measure-
ment of the mean and S.D. and a comparison of its proximity
to 0.500 g were used to assess the accuracy and reproducibil-
ity of the various devices.
2.7. Dose capacity
The goal was to draw 10 or more doses per vial. Mea-
surement of the mean and S.D. of total doses obtained and a
comparison of its proximity to 10 doses per vial were used
to assess the performance of the various devices to make
maximum use of vial capacity as well as an indirect assess-
ment of accuracy and residual/waste. From the distribution
of volumes from 5 mL vials we were able to estimate how
many draws (under optimal conditions; i.e. where there is
zero loss) might be achieved. Knowing that there was usually
a 10% overfill, we estimated, before study commencement,
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aemaining volume, the drawing up of another full dose was
ttempted. Afterwards the vial with its remaining volume
less than a full dose) was weighed (d = weight of residual
iquid and vial). This allowed the calculation of the wasted
olume (e = weight of only the residual liquid in a vial calcu-
ated by d− a = e). Following the study, staff weighed each
mpty, dry vial (a = weight of empty, dry vial) in order to
ompare with weights of full vials (b = weight of full vial)
nd assess the weight of liquid in the vial (c = weight of
nly the liquid in a full vial [b− a = c]). The participant and
taff repeated all the above steps until all seven devices were
ested.
.4. Calibration
In order to ensure that no error was introduced due to vari-
bility in the electronic balance, a calibration was performed
sing FACT (Fully Automatic Calibration TechnologyTM,
ettler-Toledo, OH, USA). This internal, automatic calibrat-
ng function was used to ensure standardization between each
ove (from centre to centre and from site to site within a cen-
re) and before any study samples were weighed. FACT was
lso run between each participant.hat ideally the percentage of 9-draw vials would be approxi-
ately 2%, 10-draw vials approximately 15%, 11-draw vials
pproximately 80% and 12-draw vials approximately 3%.
omparison of the performance of each device to these opti-
al draw values was made.
.8. Residual/waste
Using this procedure we were able to calculate e, the
esidual volume. Sum e and mean e were assessed for each
evice. The comparison within the same vial enabled us to
egate the variation due to differences in non-liquid vial com-
onents (glass, plastic, stopper, label, aluminium wrapper,
tc.).
.9. Assumptions
Several assumptions were made regarding the possible
accine configuration in a pandemic. The first was that vials
sed would be the same as those currently marketed, i.e.
mL; secondly, that the dose of flu vaccine would be the
ame as currently used, i.e. 0.5 mL; finally, that the variable
mount of over-fill per vial (often allowing more than 10
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doses to be drawn from each) would continue to be provided
by manufacturers throughout a pandemic.
2.10. Possible sources of error
One possible source of error was the difference in the
empty weight of one vial (i.e. capacity before filling) com-
pared to another. Another was the difference in the full weight
of one vial (i.e. capacity after filling and before drawing) com-
pared to another. These possible sources of error were eval-
uated by comparing weights of all empty and filled vials to
determine if there were differences within device categories.
A third potential confounding factor might be differences in
the dead-space volume of one device category compared to
another. The dead-space in a syringe is the volume of fluid that
is drawn up but not injected; this volume is trapped inside the
syringe as a function of the design of the device. This parame-
ter was evaluated in a separate bench experiment in which 40
syringes from each of the 7 device categories were weighed
empty and then filled with 0.5 mL of saline; the saline was
expelled by fully depressing the plunger and the device was
immediately weighed. The difference between the final and
the first weights was considered the dead-space volume.
2.11. Performance: ease of use, safety, preference
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doses delivered with the test devices of 0.015 mL (mg) at a
0.05 level of significance with a power of 90% assuming a
standard deviation of 0.030 mL. A target of 200 injections
per centre was set based on the above estimate. Because of
the potential for large centre-to-centre variation (due to air
shots with conventional syringes wasting up to 0.2 ml per
injection) the study was powered to be analyzed centre by
centre.
2.12.3. Statistical tests
Two-sample t-test was used to compare mean doses for
accuracy and reproducibility. Multi-variant ANOVA was
used to determine relative influence of each of the following
factors: device, subject, centre and country. Fisher exact test
compared percentages. Contingency tables using chi-squared
and McNamar tests were used to assess the difference in
dose/vial as a function of device.
2.13. Regulatory
The study was conducted in compliance with Good Clini-
cal Practices and applicable local and European Union regula-
tory requirements and directives. Ethics Committee approval
was sought for the trial at each centre. In several cases this
process was waived by the committee due to the low risk
entailed by the study; in these cases a letter exempting the
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bA standard questionnaire was administered to each par-
icipant after completing all injections within one device
ategory to obtain their assessment of following parameters:
Ease of use: ease of learning (intuitiveness), ease of draw-
ing up, legibility of calibrations/markings, air bubble for-
mation and expulsion, ease of displacement of piston, ease
of disposal, time expenditure of the procedure.
Safety: prevention of reuse, potential for needlestick
injuries, disposal issues.
Additionally, study monitors observed and recorded user
erformance on the following parameters: speed of learning
n each of the devices, correct use of each of the seven devices
nd drawing-up techniques.
.12. Statistics
.12.1. Predicate studies
A previous 2003 study in South Africa ([19]; see also [20])
howed that the average dose per injection was 0.575 mL
=0.575 g) with BD 0.5 mL SoloShotTM syringes and
.637 mL (=0.637 g) with conventional disposable syringes.
his difference (0.062 mL on average) was statistically highly
ignificant (p = 0.0025). In that trial, the standard deviation
he BD 0.5 mL SoloShotTMwas 0.037 and 0.060 with the
onventional syringes.
.12.2. Sample size determination
One hundred and eighty injections of each type in each
entre were required to detect a mean difference betweenponsor from this requirement was obtained from the chair-
erson of the Ethics Committee.
. Results
.1. Accuracy
There was a statistically significant difference in the accu-
acy of the 7 devices (p = 0.001) with devices 1 and 6 being
he most accurate (closest means to 0.500 g) and devices 4
nd 5, the least accurate (Fig. 1).
.2. Doses obtained from each vial
We observed a highly statistically significant difference
p = 0.001) amongst devices in the number of doses that could
e drawn per vial (Table 3A). We extrapolated this data to 1
illion vials used per device (Table 3B) and calculated how
any persons could be vaccinated from these 1 million vials
s a function of device (Table 3C). It is clear from our data
hat device 1 allows for the maximum number of doses to be
rawn from each vial. Table 4 shows the additional number
f persons who could be vaccinated by switching from any
f the other devices to device 1. Conversion from any other
evice to device 1 results in between 222,222 and 1,577,777
dditional persons vaccinated per million vials purchased.
hese estimates must be taken as indicative of a trend and not
s absolute figures, as any error in our study of 315 vials will
e multiplied 3000-fold when an extrapolation to a million
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Fig. 1. A comparison of the mean weights in g of 540 doses delivered by each
of the 7 devices (3780 total doses). Devices that delivers less than 0.500 g
are considered to underdose (e.g. devices 3, 4 and 7), those that deliver more
than 0.500 g to overdose (device 5) and those that deliver a mean closest to
0.500 g are the most accurate (e.g. devices 1 and 6). Error bars represent the
95% CI.
Table 3A
Actual study data (numbers in the columns under doses drawn represent the
number of vials which yielded this number of doses)
Devices Doses drawn per vial Total
7 8 9 10 11 12
1 0 0 16 19 9 1 45
2 0 1 20 18 5 1 45
3 0 4 40 1 0 0 45
4 0 6 27 9 2 0 44
5 2 28 14 1 0 0 45
6 0 2 39 5 0 0 46
7 0 5 39 1 0 0 45
Total 2 46 195 54 16 2 315
vials is made. However, despite this error the data show that
switching to this device from any of the others tested would
provide between 2 and 19% additional vaccine doses per vial
if the current 10-dose vials are used.
Fig. 2. Means of residual volumes (waste) left in vials per device category.
The least wasteful are devices 1 and 2 while the others are approximately
twice as wasteful. Error bars indicate the 95% CI.
3.3. Residual volume (waste)
The volume of liquid left in the vials after all possible
doses were drawn up was measured indirectly by weighing
the vial once user felt all possible doses had been drawn and
subtracting the weight of the dry, empty vial. The means of
these weights are shown in Fig. 2. There is a highly statisti-
cally significant difference (p = 0.001) in the residual volumes
in vials as a function of device used. Device 1 leaves the least
amount of residual volume (less than half that of devices 3–7)
and thus is the least wasteful.
3.4. Reproducibility
Reproducibility is a measure of how equally and consis-
tently the doses are drawn up from one injection to another.
There was no statistically significant difference in repro-
ducibility as measured by the standard deviation of the mean
Table 3B
Study data extrapolation to 1 million vials/device
Device Number of vials delivering the following doses, assuming 1 million vials used for each device Total
7 8 9 10 11 12
1 0 0 355555 422222 200000 22222 1000000
2 0 22222 444444 400000 111111 22222 1000000
3 0 88888 888888
4 0 136363 613636 2
5 44444 622222 311111
6 0 43478 847826 1
7 0 111111 86666622222 0 0 1000000
04545 45454 0 1000000
22222 0 0 1000000
08695 0 0 1000000
22222 0 0 1000000
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Table 3C
Number of persons who could be vaccinated from these 1 million vials as a function of device
Device Persons vaccinated per vial type Total
7 8 9 10 11 12
1 0 0 3200000 4222222 2200000 266666 9888888
2 0 177777 4000000 4000000 1222222 266666 9666666
3 0 711111 8000000 222222 0 0 8933333
4 0 1090909 5522727 2045454 500000 0 9159090
5 311111 4977777 2800000 222222 0 0 8311111
6 0 347826 7630434 1086956 0 0 9065217
7 0 888888 7800000 222222 0 0 8911111
Table 4
Additional number of persons who could be vaccinated by switching from any of the other devices to device 1
Device Total persons vaccinated By switching from Additional persons vaccinated per 1 million vials
1 9888888 NA
2 9666666 Device 2–1 222222
3 8933333 Device 3–1 955555
4 9159090 Device 4–1 729798
5 8311111 Device 5–1 1577777
6 9065217 Device 6–1 823671
7 8911111 Device 7–1 977777
of dose weights, with values varying from 0.03395 g for
device 3 to 0.06631 g for device 5.
3.5. Dead-space volumes
In an attempt to explain the differences observed in accu-
racy and dose-sparing characteristics of the devices, we
tested the dead-space by weighing 40 syringes from each
device category, then, after filling them with 0.5 mL of saline
and expelling it, we weighed the device again. The differ-
ence between the latter weight and the former was consid-
ered the dead-space volume. Fig. 3 shows that devices 1
and 2 had statistically significant lower dead-space volumes
than the other devices. Device 1 had the lowest dead-space
volume.
3.6. Possible sources of error
One possible source of error is the difference in the empty
weight of one vial (i.e. capacity before filling) compared to
another. We found no statistical difference (p = 0.751) in the
dry weight of vials used in this study as a function of their
use in different devices. Another possible source of error is
the difference in the full weight of one vial (i.e. capacity
after filling and before drawing) compared to another. We
3.7. Monitoring results
One study staff nurse (EF) observed each injection for a
number of parameters. Virtually no users requested to see
the instructions for use or a demonstration of the product
or practiced with the device beforehand. However, almost
all were given verbal explanations regarding the function
of each device. In this regard the exposure to the devices
mimics that of a pandemic, where detailed training for all
F
d
sfound no statistical difference (p = 0.829) in the filled weight
of vials used in this study as a function of their use in dif-
ferent devices. Variability in either the dry or full weight of
vials cannot, therefore, be used to explain the difference in
number of doses obtained from vials with different devices.
Multivariate analysis showed that the factor responsible for
the differences found in parameters tested was the device and
not the factors of country, site, clinician or vial.ig. 3. The means of dead-space volumes (n-40 per device) for the seven
evices tested. Devices 1 and 2 had statistically significantly lower dead-
pace volumes than the other devices.
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users might be impossible. For all devices except number
2 almost no users required any additional training during
the injection sequence. Almost a third of those using device
2 did require such training. Device 2 was the only device
with a fixed dose feature (0.5 mL) and an automatic lock-
ing mechanism to prevent reuse (i.e. auto-disable syringe).
It was the only device that appeared to be different from
what the clinicians would normally use. For all devices
except number 2 the clinicians used them correctly virtu-
ally all the time (>97.8%). For device 2 only 93.3% of users
used it correctly, a difference that was statistically significant
(p = 0.01).
3.8. Clinician feedback results
There was no statistical difference amongst devices
regarding ease of use. There was no statistical difference
amongst devices in the adequacy of training given; almost
all clinicians felt it was adequate. There was a statistical dif-
ference amongst devices in ability to draw up using one’s
usual technique; device 2 accounted for this difference, as
it required significant numbers of clinicians to change tech-
nique. There was a statistical difference amongst devices in
terms of amount of time to draw up and administer an injec-
tion; devices 1 and 2 took less time to operate, while devices
3 and 7 took more.
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suppliers), one may even get 11 or 12 doses from a vial. There
are enormous financial benefits that will accrue if, from each
vial, 20% more vaccine is saved; this may be expected to
translate into 20% lower vaccine costs, 20% less workload
for vaccinators and 20% greater numbers of persons vacci-
nated.
4.2. One should stock a syringe that is safe and simple
to use
In the event of a pandemic, where tens of millions of
persons must be vaccinated in a short period of time, the
engagement of many non-professional persons as vaccina-
tors is inevitable. In this case, insisting on previously used
injecting conventions (e.g. two-needle per injection) is dis-
tracting and irrelevant as these people will not have had any
previous experience. Techniques, in this case, must be the
simplest possible, easy to teach and learn as well as free of
any additional risk. A one-needle per injection technique is
the easiest to learn, safer for the injector, simpler logistically
and produces less sharps waste overall.
4.3. One should stock a syringe that has an integrated
needle
A device with an integrated needle requires the injector
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a. Discussion
With ‘avian flu’ literally staring us in the face and the
atastrophic experience of previous influenza pandemics as
backdrop, it is imperative that wise planning, backed by
olitical will and resources, take place now. In addition to
tocking anti-viral drugs and preparing vaccine manufactur-
rs for the challenge ahead, national governments have a duty
o stock the means of delivery for the vaccine. Officials and
edical decision makers must be asking the question, what
ould constitute an optimal injecting device for inﬂuenza
accine in a pandemic? We would like to offer the following
uggested answers as a prelude to discussing the results of
ur study.
.1. One should stock a syringe that reduces vaccine
astage and increases dosages per vial
It will be important to reduce vaccine wastage (given the
nevitability of a shortage of vaccine); therefore, devices with
low dead-space feature will provide important advantages.
xperience shows that by using a low dead-space device and
y appropriate drawing-up technique (expelling excess vac-
ine back into the vial rather than into the air when getting
id of bubbles or aligning meniscus to dose line) one may
ncrease the number of doses drawn from a 10-dose vial
rom an average of 8 to an average of 10. In some instances,
nvolving over-filled vials (a common practice by vaccineo use the same needle to inject as was used for drawing up.
his technique is not currently used in many health-care set-
ings (e.g. the UK), but is the most common practice in many
ettings worldwide (including parts of the USA and Europe).
ntegrated needles save doses (due to dead-space engineer-
ng), save time (spent changing the drawing-up needle), are
impler to stock and deliver logistically (only one stocking
tem). They are generally considered to be safer because there
s only one-needle requiring disposal.
.4. One should stock a syringe which manufacturers
an supply in the volumes needed
A three-piece syringe consists of a barrel, a plunger
nd a stopper on the end of the plunger. Newer manufac-
uring techniques have incorporated the stopper into the
lunger, making these devices two-piece rather than three-
iece. Two-piece syringes used for influenza vaccination
re ideal in that they are less expensive, perform this func-
ion virtually indistinguishably from three-piece and are
vailable in volumes that manufacturers have capacity to
eliver.
.5. One should stock a needle whose length permits
njectors to reach muscle without hitting nerves, vessels
r bone
The official recommendations [21] for influenza vacci-
ations by the Centers for Disease Control are as follows:
dults and older children should be vaccinated in the deltoid
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Table 5
A summary of key findings on each device
Device number Name/description Accuracy Dose-sparing Minimal residual volume Speed in use
1 Flu+ ++++ ++++ ++++ ++++
2 SoloShot IX +++ +++ +++ ++++
3 Plastipak Luer slip + ++ + +
4 Plastipak Luer slip + ++ + +++
5 Injekt Luer slip + + + ++
6 Monoject Luer slip ++++ ++ ++ +++
7 Terumo Luer slip ++ ++ + +
muscle. A needle length ≥1 in. can be considered for these
age groups because needles ≤1 in. might be of insufficient
length to penetrate muscle tissue in certain adults and older
children. Infants and young children should be vaccinated
in the anterolateral aspect of the thigh. ACIP recommends a
needle length of 7/8–1 in. for children aged ≤12 months for
intramuscular vaccination into the anterolateral thigh. When
injecting into the deltoid muscle among children with ade-
quate deltoid muscle mass, a needle length of 7/8–1.25 in. is
recommended.
Table 5 presents a summary of the key findings in our
study of seven candidate devices. It would appear that there
are compelling reasons to recommend device 1 for stocking
in the event of an influenza pandemic. Device 1 yielded more
doses per vial, probably because it has significantly lower
dead-space volumes (Fig. 4). The additional persons vacci-
nated per million vials with this device is striking, and its
use could probably lead to significant decreases in morbidity
and mortality. In addition to sparing doses and ‘stretching’
the vaccine supply, the use of device 1 would likely mean
considerable financial savings to health-care systems due to
less vaccine wastage and more efficient (speedier) injections.
How much this savings would be is difficult to calculate. We
do not know what the cost of the pandemic vaccine will be
or, more importantly, the total cost of caring for victims who
could have been spared had they been vaccinated. However,
if the current cost of flu vaccine is used as a reference, it
is clear that the financial savings which would accrue from
vaccine savings on the scale reported here would more than
cover the additional costs of stockpiling the device.
Device 1 is a two-piece (plastic plunger + barrel) syringe
with an integral (non removable) needle. Unlike many con-
ventional syringes, the plunger tip is pointed (Fig. 4) to
minimize vaccine residue upon completion of each dose.
Pharmaceutical manufacturers are advised by the US Phar-
macopeia Formulary [22] to over-fill drug vials by 20–25%
to compensate for wastage, from, among other factors, the
dead-space volumes of standard syringes. There is, how-
ever, no guarantee that vaccine manufacturers, pressed by
the inevitable vaccine shortage, would continue to offer this
(or any) degree of overfill during a pandemic.
Inevitably some vaccine is discarded with the syringe
following use. Injection devices with less dead-space, also
known as ‘dose-sparing’ devices, can increase the amount
of useable vaccine in a multi-dose vial allowing for greater
distribution of the vaccine. Clinical testing and customer-
F d end o
c e (red)ig. 4. The syringe on the left has a plunger tip that fits into the cone-shape
onventional device on the right, where a considerable amount of dead-spacf the barrel, decreasing the amount of dead (waste) space. Compare to the
remains when the plunger is pushed in.
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documented experience have shown that the available vaccine
can be extended by 7–10% through the use of these devices.
Therefore the use of injection devices with dose-sparing capa-
bilities is a relatively low cost solution to maximizing flu
vaccination yields.
In summary, our study attempts to bring to light a neglected
aspect of pandemic planning, the choice of a syringe which
will waste as little vaccine as possible while being accurate,
reliable and available in quantities sufficient to supply world-
wide demand. One syringe, device 1 in our study, seems to
rise above the others in this regard and its use could prove to
be life-saving in the event of a pandemic of influenza.
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